Healthlead operates as a holding company through subsidiaries by investing in drugstores and a health product distributor who collaborates with research institutions to develop and distribute innovative health products.
| 6M24 | 6M23 | 2023 | 2022 |
|---|
| Revenues | 966.91 | 792.11 | 1,659.31 | 1,538.21 |
| Expenses | 926.54 | 751.75 | 1,558.59 | 1,389.82 |
| Net Profit (Loss) | 30.30 | 28.76 | 74.68 | 118.23 |
| Assets | 1,429.58 | 1,274.50 | 1,382.35 | 1,288.19 |
| Liabilities | 472.03 | 352.70 | 414.29 | 346.20 |
| Shareholders' Equity | 957.55 | 921.79 | 968.05 | 941.99 |
| Operating | 37.46 | 8.82 | 91.26 | 136.20 |
| Investing | -165.20 | -56.33 | 177.28 | -624.51 |
| Financing | -60.16 | -63.92 | -80.08 | -70.34 |
| EPS (Baht) | 0.11 | 0.11 | 0.27 | 0.43 |
| GP Margin (%) | 22.43 | 22.14 | 23.06 | 24.76 |
| NP Margin (%) | 3.13 | 3.63 | 4.50 | 7.69 |
| D/E Ratio (x) | 0.49 | 0.38 | 0.43 | 0.37 |
| ROE (%) | 8.11 | 10.46 | 7.82 | 13.08 |
| ROA (%) | 7.42 | 10.03 | 7.50 | 12.33 |
The Group aims to expand its branch continuously, targeting Bangkok and its vicinity due to the high market value. The target is to open 20 new branches in 2024. In addition, the Group also plans to launch innovative products under its own brands and expand its distribution channels.
- Aim to operate with fairness, legitimacy, and transparency.
- Strictly comply with the law and regulations.
- Operate in consistent with labor law and concerns regarding human rights.
- Show responsibility to customers by providing high quality products and customer services, with accurate and updated information, and keeping client confidentiality.
- Implement a green campaign by reducing usage of plastic bags and paper boxes. Implementing ERP systems to reduce paper usage. The Group initiated a pioneering project, by applying e-tax to business partners, in order to reduce paper use, for partners who are ready for the transformation.
- Place its importance on a healthy community and support sustainable development. The Group has participated in diverse activities in various aspects such as public health, education, and religion.
The Group invests in pharmacy chains and collaborative research with external teams to commercialize innovative health products. It owns four pharmacy brands with 55 branches in Bangkok and its vicinity. The Group also has two innovative product brands: 'Prime', dietary supplement, and 'Besuto', health and hygiene products.
In 6M2024, the Group recorded a total revenue of 947.35 million baht, representing a 21.07% growth YOY. The primary source of revenue continued to be retail sales, accounting for 98.99% of the total.
Revenue from all product categories grew YOY, with the highest growth rate of 30.05% from Personal healthcare. This was followed by a 27.11% growth in Medical food. Other income increased by 35.73% YOY due to an increase in the number of branches and sales areas, resulting in higher service fees.
Icare Health Co., Ltd., a subsidiary, recorded a gain of 6.45 million baht from the disposal of non-current assets classified as held for sale. This asset was an idle piece of land with a warehouse building, which was sold and transferred on February 8, 2024. The Group's net profit was 30.30 million baht, showing a 5.33% growth YOY.
- As of 30 June 2024, the Group had a total of 55 branches, by adding three branches in Q2-2024 in Bangkok and its vicinity.
- Certified as Accredited Pharmacy by The Office of Community Pharmacy Accreditation (Thailand) to legitimately join the National Health Security System Program or the so-call "Golden Card" 30 Baht health care scheme.
- VAT REFUND FOR TOURISTS is available in all branches.
- Implemented e-Tax Invoice & e-Receipt and joined 'Easy e-Receipt program', the government's domestic consumption stimulus plan, from January 1, 2024 to February 15, 2024.
- Prime KIN product has won the gold medal for innovation at the 2024 Japan Design, Idea & Invention Expo.
- Since founding the drugstore 30 years ago, the Group has sourced from two major distributors. The partnership has gone well. However, the Group has regularly reviewed new suppliers to ensure it secures sufficient products.
- In terms of competition risk, the Group focuses on expanding branches to strategic locations in Bangkok and having pharmacists stationed at all branches to guarantee superior quality of services.
- The Group is widely recognized in pharmacist professional group, as it has been offering internship programs for pharmaceutical students from leading universities for years. This has efficiently mitigated the risk of pharmacist shortage.
- Gold Medal for the invention Prime B0051 plus at the 2021 Japan Design, Idea & Invention Expo, August 18-20, 2021
- Silver Medal for the Invention Innovation Entitled: BESUTO-12 at the iCAN 2020 (Toronto, Canada), August 29, 2020
- Special Award in recognition of excellent invention/innovation of BESUTO-12 at the iCAN 2020 (Toronto, Canada), August 29, 2020
- Silver Medal for SPECIAL EDITION 2022 from Cell Matrix Technology Prime VISON Product - INVENTION GENEVA EVALUATION DAYS, March 28, 2022
- Gold Medal for the invention Prime MOVX2 -2022 Japan Design, Idea & Invention Expo, July 1-3, 2022
- Gold Medal for the invention Prime KIN - 2024 Japan Design, Idea & Invention Expo, July 5-7, 2024
| as of 28/06/24 | HL | SERVICE | mai |
|---|---|---|---|
| P/E (X) | 34.82 | 123.70 | 40.95 |
| P/BV (X) | 2.84 | 2.41 | 1.79 |
| Dividend yield (%) | 1.46 | 2.00 | 2.06 |
| 28/06/24 | 28/12/23 | 30/12/22 | |
|---|---|---|---|
| Market Cap (MB) | 2,801.60 | 2,828.80 | 6,691.20 |
| Price (B/Share) | 10.30 | 10.40 | 24.60 |
| P/E (X) | 34.82 | 35.81 | 62.92 |
| P/BV (X) | 2.84 | 3.02 | 7.38 |
